These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 6375562)
1. Pharmacokinetics of ceftazidime in normal and uremic subjects. Leroy A; Leguy F; Borsa F; Spencer GR; Fillastre JP; Humbert G Antimicrob Agents Chemother; 1984 May; 25(5):638-42. PubMed ID: 6375562 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of ceftazidime in patients with renal insufficiency. Welage LS; Schultz RW; Schentag JJ Antimicrob Agents Chemother; 1984 Feb; 25(2):201-4. PubMed ID: 6370127 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Leroy A; Humbert G; Fillastre JP Antimicrob Agents Chemother; 1981 Jun; 19(6):965-71. PubMed ID: 6455967 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Blum RA; Kohli RK; Harrison NJ; Schentag JJ Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847 [TBL] [Abstract][Full Text] [Related]
5. Effect of decreased renal function on the pharmacokinetics of ceftazidime. Ackerman BH; Ross J; Tofte RW; Rotschafer JC Antimicrob Agents Chemother; 1984 Jun; 25(6):785-6. PubMed ID: 6378087 [TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Kashuba AD; Ballow CH; Forrest A Antimicrob Agents Chemother; 1996 Aug; 40(8):1860-5. PubMed ID: 8843294 [TBL] [Abstract][Full Text] [Related]
7. Effect of hemodialysis on ceftazidime pharmacokinetics. Nikolaidis P; Tourkantonis A Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438 [TBL] [Abstract][Full Text] [Related]
8. Cefsulodin pharmacokinetics in patients with various degrees of renal function. Matzke GR; Keane WF Antimicrob Agents Chemother; 1983 Mar; 23(3):369-73. PubMed ID: 6847169 [TBL] [Abstract][Full Text] [Related]
9. Distribution of ceftazidime in ascitic fluid. Benoni G; Arosio E; Raimondi MG; Apolloni E; Passarella E; Lechi A; Velo GP Antimicrob Agents Chemother; 1984 Jun; 25(6):760-3. PubMed ID: 6378086 [TBL] [Abstract][Full Text] [Related]
10. The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole. Sobue S; Tan K; Layton G; Leclerc V; Weil A Br J Clin Pharmacol; 2004 Jun; 57(6):773-84. PubMed ID: 15151523 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tissue penetration of ceftazidime: studies on lymph, aqueous humour, skin blister, cerebrospinal and pleural fluid. Walstad RA; Hellum KB; Blika S; Dale LG; Fredriksen T; Myhre KI; Spencer GR J Antimicrob Chemother; 1983 Jul; 12 Suppl A():275-82. PubMed ID: 6352632 [TBL] [Abstract][Full Text] [Related]
18. Cefmenoxime pharmacokinetics in patients with renal insufficiency. Polk RE; Sica DA; Kerkering TM; Kline BJ; Patterson PM; Baggett JW Antimicrob Agents Chemother; 1984 Sep; 26(3):322-7. PubMed ID: 6095752 [TBL] [Abstract][Full Text] [Related]
19. Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. Merdjan H; Tarral A; Das S; Li J J Clin Pharmacol; 2017 Feb; 57(2):211-218. PubMed ID: 27402250 [TBL] [Abstract][Full Text] [Related]
20. Ceftazidime disposition in acute and stable cystic fibrosis. Leeder JS; Spino M; Isles AF; Tesoro AM; Gold R; MacLeod SM Clin Pharmacol Ther; 1984 Sep; 36(3):355-62. PubMed ID: 6432400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]